Camidge DR et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. J Thorac Oncol 2021;16(12):2091-108. Abstract
Camidge DR et al. Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol 2021;16(6):1017-29. Abstract
Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 2022;23(6):781-92. Abstract
Dziadziuszko R et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol 2021;39(11):1253-63. Abstract
Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract
Felip E et al. Preliminary results from PROPEL: A phase 1/2 study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC. ESMO 2021;Abstract 140P.
Felip E et al. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC as identified by liquid (LBx) or tissue (TBx) biopsy. WCLC 2021;Abstract P45.03.
Gainor JF et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22(7):959-69. Abstract
Garon E et al. TROPION-PanTumor01: Updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. WCLC 2021;Abstract MA03.02.
Garon EB et al. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. ESMO 2021;Abstract LBA49.
Gay CM et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39(3):346-60.e7. Abstract
Horn L et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial. JAMA Oncol 2021;7(11):1617-25. Abstract
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Canc Disc 2022;12(1):74-89. Abstract
Knelson EH et al. PARP inhibitors in small-cell lung cancer: Rational combinations to improve responses. Cancers (Basel) 2021;13(4):727. Abstract
Kolakowski GR et al. Pre-clinical characterization of potent and selective next-generation RET inhibitors. AACR 2021;Abstract 1464.
Krebs M et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. ASCO 2022;Abstract 9008.
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Eng J Med 2022;386(3):241-51. Abstract
Martinez-Marti A et al. COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. ESMO 2021;Abstract LBA42.
Miyazaki I et al. Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations. Mol Cancer Ther 2021;20(12_Supplement):P06-02. Abstract
Ou S-HI et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin Oncol 2022;[Online ahead of print]. Abstract
Owonikoko TK et al. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). ASCO 2021;Abstract 8510.
Paz-Ares L et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(2):198-211. Abstract
Paz-Ares L et al. Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: phase III randomized ATLANTIS trial. WCLC 2021;Abstract PL02.03.
Ponce Aix S et al. 2SMALL (NCT04253145) phase I part: Lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts). SITC 2021;Abstract 464.
Ponce Aix S et al. A Phase 1b Study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (ep) or carboplatin (ec) in patients (pts) with first-line (1l) extensive-stage (ES) small cell lung cancer (SCLC): Updated results. ELCC 2021;Abstract 50P.
Reck M et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 2021;6(5):100273. Abstract
Reck M et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 2021;39(21):2339-49. Abstract
Riely GJ et al. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer Discov 2021;11(7):1688-99. Abstract
Schoffski P et al. BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. ASCO 2021;Abstract 3008.
Skoulidis F et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021 Jun 24;384(25):2371-2381. Abstract
Spicer J et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8503.
Spigel DR et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301-11. Abstract
Spira A et al. Amivantamab in non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation: Initial results from CHRYSALIS. WCLC 2021;Abstract OA15.03.
Spira A et al. DatopotamabdDeruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study. J Thorac Oncol 2021;16(3S):S106-7. Abstract
Wakelee HA et al. IMpower101: Primary results of a phase III global study of atezolizumab vs best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8500.
Weiss J et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021;22(5):449-60. Abstract
Wolf J et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. ASCO 2021;Abstract 9020.
Yoshioka H et al. Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC. ASCO 2021;Abstract 9111.
Zhou C et al. IMpower010: Biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO IO 2021;Abstract 20.